An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma. Sacco, A., Messer, K., Leidner, R. S., Colevas, A., Nieva, J. J., Chau, N., Nangia, C., Pinsky, B., Gold, K. A., Daniels, G. A., Cohen, E. W. AMER SOC CLINICAL ONCOLOGY. 2017

View details for DOI 10.1200/JCO.2017.35.15_suppl.TPS6092

View details for Web of Science ID 000411931705088